Human Milk Oligosaccharides Market Size, Share & Trends Analysis Report By Application (Infant Formula, Functional Food & Beverages, Food Supplements), By Region, And Segment Forecasts, 2020 - 2027

Report Overview

The global human milk oligosaccharides market size was estimated at USD 19.3 million in 2019 and is expected to expand at a CAGR of 23.0% during the forecast period. Increasing concerns among consumers regarding gut health and the growing consumption of dietary supplements are expected to drive the growth. Human Milk Oligosaccharides (HMOs) act as prebiotics in the human body and help maintain gut health. They promote bacterial growth, especially bifidobacteria genus, in the gut, which helps improve metabolic activity. The antimicrobial protection and prebiotic functions of the product allow them to be used in various food products, including pharmaceutical and medicinal food and infant formulas.

Lack of technology for large-scale production, high R&D cost, and stringent government regulations are likely to restrain the HMO market growth. Infant formula is the largest application segment for the product, which promote health and prevent diseases in infants. Moreover, these play a vital role in brain development and memory enhancement in humans.

The primary functions of human milk oligosaccharides include the prevention of infection, the supply of sialic acid for brain development, and prebiotic effects. Infant formulas derived from bovine milk contain less concentration of oligosaccharides compared to those obtained from human milk.

Several enzymes and chemicals used for manufacturing human milk oligosaccharides are very expensive and have limited availability. This factor is likely to hinder the market growth. Infant formula is the dominant application segment for HMOs, followed by functional food and beverages. The demand for high nutrition food for children as well as adults is another factor driving the human milk oligosaccharides market.

Human milk oligosaccharides are essential components of breast milk. They promote optimal health and help prevent certain diseases among not just infants but adults as well. They support digestive, immune, and brain development for an infant. In the case of adults, HMO supplements are found to be helpful for increasing beneficial bacteria in the gut. However, breast milk is not available for all infants, which leads to the synthetic production of HMOs through various production methods.

Incorporation of human milk oligosaccharides in functional food and beverages promotes the growth of good bacteria and eliminates harmful bacteria, including salmonella, listeria, and campylobacter. Dairy products dominate the functional food market. There is a high demand for functional food and beverages with prebiotic properties.

Human milk oligosaccharides not only provide prebiotic effects but also stimulate the neurological health of human beings. These properties are expected to drive the demand for HMO in functional food and beverages. Companies including Inbiose NV; Glycom A/S; ZuChem, Inc.; and Glycosyn LLC have been making efforts to develop human milk oligosaccharides for functional food and beverages.

Application Insights

Among applications, infant formula dominated the global market in 2019, accounting for nearly 81% of the overall revenue share in 2019. The demand for HMOs in designing infant formulas is increasing owing to the beneficial properties of HMOs, such as prevention from infection, prebiotic effects, memory enhancement, and brain development, and gut health maintenance.

Functional food and beverages was the second-largest application segment, accounting for over 9.1% of the market revenue in 2019. Owing to the various health benefits offered by HMO, its consumption of in functional food and beverage formulations is expected to grow significantly over the forecast period, thereby driving the product demand.

The use of HMOs in dietary supplements offer benefits, such as immune support, protection against bacterial and viral infections, digestive comfort, and brain function support. Increasing healthcare costs, changing lifestyles, and rise in the geriatric population are the major factors driving the food supplements industry, further supported by rising consumer health awareness and increasing disposable incomes.

Regional Insights

North America held the largest revenue share of the market for human milk oligosaccharides in 2019. The presence of numerous prominent infant formula and baby food manufacturers along with technological advancements are expected to boost the regional market growth in the forthcoming years.

Growing demand for infant food coupled with the presence of a large number of HMO manufacturers and regulatory approvals for HMO as an ingredient in infant formula is anticipated to augment the market growth in Europe. The U.K. has the lowest breastfeeding rate owing to the cuts in public health funding, lack of knowledge about the health benefits of breast milk, and a negative attitude toward breastfeeding in public, which indicates a huge potential for product penetration in the country.

Asia Pacific HMO market is expected to be driven due to factors such as rising population, mortality rate, disposable income, and consumer awareness regarding health and hygiene. Rising concerns regarding gut diseases, high blood pressure, diabetes, and rickets among other chronic diseases have resulted in an increased demand for functional food and beverages, which is expected to propel the regional demand for human milk oligosaccharides. In addition, India and China are the rapidly growing markets for dietary supplements and baby food, which is anticipated to further fuel the product demand over the forecast period.

Human Milk Oligosaccharides Market Share Insights

Many manufacturers focus on extensive R&D for developing low-cost technologies to produce HMO in large scales. Presently, the market for HMOs is niche and has considerable scope for development in applications, including functional foods and beverages and food supplements. A significant share of HMOs manufactured currently goes into infant formula application. To cater to the growing demand for the product, manufacturers are deploying strategies such as partnerships, agreements, and capacity expansions.

Prominent market participants have invested in R&D activities over the years to innovate their product offerings. For instance, in February 2019, Jennewein Biotechnologie GmbH, a Germany-based functional sugars manufacturer, partnered with Yili.Com Inc., a China-based dairy products manufacturer, to research on infant microbiome and human milk oligosaccharides. This strategy was intended to develop innovative, HMO-based infant formula and was targeted at customers in China. Such developments/strategies are likely to surface over the forecast period, given the rising competition in the market.

Inbiose NV; Elicityl S.A.; Jennewein Biotechnologie GmbH; Glycom A/S; Medolac Laboratories; ZuChem Inc.; and Glycosyn LLC are the key companies operating in the HMO market. The requirement of a complex technological process for manufacturing HMOs has been discouraging new entrants at regional levels.

Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global human milk oligosaccharides market report on the basis of application and region:

• Application Outlook (Volume, Tons; Revenue, USD Thousand, 2016 - 2027)

  • Infant Formula

  • Functional Food & Beverages

  • Food Supplements

  • Others

• Regional Outlook (Volume, Tons; Revenue, USD Thousand, 2016 - 2027)

  • North America

    • The U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • The U.K.

    • France

  • Asia Pacific

    • China

    • India

    • Japan

  • Central & South America

    • Brazil

  • Middle East & Africa

    • UAE